Advertisement

MicroSite Collections

  • Subclonal TP53 copy number is associated with prognosis in multiple myeloma
    Vallari Shah, David C. Johnson, Amy L. Sherborne, Sidra Ellis, Frances M. Aldridge, Julie Howard-Reeves, Farzana Begum, Amy Price, Jack Kendall, Laura Chiecchio, Suvi Savola, Matthew W. Jenner, Mark T. Drayson, Roger G. Owen, Walter M. Gregory, Gareth J. Morgan, Faith E. Davies, Richard S. Houlston, Gordon Cook, David A. Cairns, Graham Jackson and Martin F. Kaiser
  • IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos
    Pasquale L. Fedele, Simon N. Willis, Yang Liao, Michael S. Low, Jai Rautela, David H. Segal, Jia-Nan Gong, Nicholas D. Huntington, Wei Shi, David C. S. Huang, George Grigoriadis, Julie Tellier and Stephen L. Nutt
  • Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
    Matthieu Jestin, Ygal Benhamou, An-Sofie Schelpe, Elien Roose, François Provôt, Lionel Galicier, Miguel Hié, Claire Presne, Pascale Poullin, Alain Wynckel, Samir Saheb, Christophe Deligny, Aude Servais, Stéphane Girault, Yahsou Delmas, Tarik Kanouni, Alexandre Lautrette, Dominique Chauveau, Christiane Mousson, Pierre Perez, Jean-Michel Halimi, Anne Charvet-Rumpler, Mohamed Hamidou, Pascal Cathébras, Karen Vanhoorelbeke, Agnès Veyradier and Paul Coppo
  • RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature
    Michael A. Chapman, Jonathan Sive, John Ambrose, Claire Roddie, Nicholas Counsell, Anna Lach, Mahnaz Abbasian, Rakesh Popat, Jamie D. Cavenagh, Heather Oakervee, Matthew J. Streetly, Stephen Schey, Mickey Koh, Fenella Willis, Andres E. Virchis, Josephine Crowe, Michael F. Quinn, Gordon Cook, Charles R. Crawley, Guy Pratt, Mark Cook, Nivette Braganza, Toyin Adedayo, Paul Smith, Laura Clifton-Hadley, Roger G. Owen, Pieter Sonneveld, Jonathan J. Keats, Javier Herrero and Kwee Yong
  • Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis
    Giovanna Lucchini, Rebecca Marsh, Kimberly Gilmour, Austen Worth, Zohreh Nademi, Anupama Rao, Claire Booth, Persis Amrolia, Juliana Silva, Robert Chiesa, Robert Wynn, Kai Lehmberg, Itziar Astigarraga, Tayfun Güngör, Jan Stary, Despina Moshous, Marianne Ifversen, Daniel Zinn, Michael Jordan, Ashish Kumar, Takahiro Yasumi, Paul Veys and Kanchan Rao
  • Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma
    Christoph Driessen, Rouven Müller, Urban Novak, Nathan Cantoni, Daniel Betticher, Nicolas Mach, Axel Rüfer, Ulrich Mey, Panagiotis Samaras, Karin Ribi, Lenka Besse, Andrej Besse, Catherine Berset, Stephanie Rondeau, Hanne Hawle, Felicitas Hitz, Thomas Pabst and Thilo Zander
  • Beyond NEOD001 for systemic light-chain amyloidosis
    Cindy Varga, Suzanne Lentzsch and Raymond L. Comenzo
  • Donor-derived MDS/AML in families with germline GATA2 mutation
    Pallavi Galera, Amy P. Hsu, Weixin Wang, Stephenie Droll, Rui Chen, Jason R. Schwartz, Jeffery M. Klco, Sally Arai, Luke Maese, Christa Zerbe, Mark J. Parta, Neal S. Young, Steven M. Holland, Dennis D. Hickstein and Katherine R. Calvo
  • How I treat the older adult with sickle cell disease
    Swee Lay Thein and Jo Howard
  • How I diagnose and treat venous thromboembolism in sickle cell disease
    Arun S. Shet and Ted Wun

Pages